Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 5/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 2/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | PRF1 | P14222 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL615000 | 0.97 | CLK4 (0.42) | CLK4PGRMAOBPRKDCXDH | |
| SCHEMBL3231644 | 0.79 | MMP3 (0.39) | PGRPRKDCNOTUM | |
| SCHEMBL14102137 | 0.78 | CLK4 (0.45) | CLK4PGRMAOBPRKDCXDH | |
| SCHEMBL27803799 | 0.77 | CLK4 (0.50) | CLK4PGRMAOBXDHSLC22A12 | |
| Ethylene SCHEMBL4679355 | 0.73 | IDO1 (0.36) | LRRK2IDO1BACE1 | |
| SCHEMBL16070836 | 0.73 | PARP10 (0.40) | PRKDCNOTUM | |
| SCHEMBL13112846 | 0.73 | HTR2C (0.53) | PGRIDO1NOTUM | |
| SCHEMBL16543132 | 0.73 | L3MBTL1 (0.42) | CLK4PGRMAOBNOTUM | |
| SCHEMBL10198086 | 0.73 | MAT2A (0.45) | NOTUM | |
| SCHEMBL421011 | 0.72 | CLK4 (0.45) | CLK4PGRMAOBXDHSLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1453501-B1 | N- ARYL-N'-ARYLCYCLOALKYL-UREA DERIVATIVES AS MCH ANTAGONISTS FOR THE TREATMENT OF OBESITY | SCHERING CORP (US) | 2008-08-13 | — | — | EP | disclosed |
| US-7348328-B2 | MCH antagonists for the treatment of obesity | SCHERING CORPORATION (US) | 2008-03-25 | — | — | US | disclosed |
| EP-1453501-A1 | N- ARYL-N'-ARYLCYCLOALKYL-UREA DERIVATIVES AS MCH ANTAGONISTS FOR THE TREATMENT OF OBESITY | SCHERING CORPORATION (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20040122017-A1 | MCH antagonists for the treatment of obesity | SCHERING CORPORATION | 2004-06-24 | — | — | US | disclosed |
| WO-2003047568-A1 | N-ARYL-N'-ARYLCYCLOALKYL-UREA DERIVATIVES AS MCH ANTAGONISTS FOR THE TREATMENT OF OBESITY | SCHERING CORPORATION (US) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122017-A1 | MCH antagonists for the treatment of obesity | MCHR1, MCHR2, MC4R | CLK4 3065/4885PGR 2611/4885MAOB 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.